Nabriva Therapeutics PLC (STU:NTY)
€ 1.25 0.02 (1.63%) Market Cap: 2.76 Mil Enterprise Value: 1.62 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 39/100

Q3 2022 Nabriva Therapeutics PLC Earnings Call Transcript

Nov 10, 2022 / 09:30PM GMT
Release Date Price: €2 (-4.76%)
Operator

Welcome to the Nabriva Therapeutics Third Quarter 2022 Financial Results Call and Corporate Update. (Operator Instructions) Please note, this event is being recorded. I would now like to turn the conference over to Mr. Dan Dolan, CFO. Please go ahead.

Daniel Dolan
Nabriva Therapeutics plc - CFO

Thank you, and good afternoon, everyone. Welcome to Nabriva's Conference Call and Webcast where we'll be discussing the Third Quarter 2022 Earnings and providing a Business Update. The slides for today's presentation are posted on the company's website, www.nabriva.com, and can be found under the Investors tab in the Events and Presentations section. We recommend that you refer to the presentation, as we will be using those slides for today's discussion.

Before we begin on Slide 2, I would like to remind everyone that this conference call and webcast will contain forward-looking statements about the company. These statements are subject to risks and uncertainties that could cause actual results to

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot